Skip to main content
Premium Trial:

Request an Annual Quote

Diagnostic Collaboration to Combat Antimicrobial Resistance Launches

NEW YORK (360Dx) – AdvaMedDx, an association representing manufacturers of diagnostic tests, recently announced a global stakeholder initiative to use diagnostic tests in the fight against antimicrobial resistance, proposing collaboration among major industry organizations in the effort.

Several leading industry stakeholders have inked a commitment that serves as a framework for collaborative action, AdvaMedDx said, adding the initiative "outlines specific goals for leveraging existing diagnostic solutions and investing in improvements and access." AdvaMedDx closely collaborated with the Joint United Nations Program on HIV/AIDS (UNAIDS), Becton Dickinson, and others in launching the initiative.

To develop solutions that tackle the global health crisis, several global stakeholders have signed on to the commitment, including international diagnostics associations and companies. They include the British In Vitro Diagnostics Association; CBDL, the Brazilian Chamber for In Vitro Diagnostics; MedTech Europe; Abbott; Alere; Amplex Diagnostics; Becton Dickenson; Beckman Coulter; BioMérieux; Bio-Rad Laboratories; Cepheid; CIGA Healthcare; Erba Molecular; Hologic; Mast Group; Micronics; Mologic; Momentum Bioscience; Oxford Impedance Diagnostics; Philips Healthcare; QuantuMDx Group; Roche; and Thermo Fisher Scientific.

The initiative comes as current trends project antimicrobial resistance could cause up to 10 million deaths annually by 2050, AdvaMedDx said.

It noted that the commitment highlights the immediate benefits of leveraging existing diagnostic tests.

AdvaMedDx invited the industry stakeholders to commit to building a long-term economic case for diagnostics as a public good in the fight against drug-resistant infections; establishing public-private partnerships to develop health systems and create wide-scale access to diagnostics; work to ensure effective global utilization of diagnostics; and advocate for research and development investments, funding, simplified regulatory processes, and sustainable reimbursement policies to encourage development.